Ivonescimab and Antibody-Drug Conjugates Reshape First-Line NSCLC Questions

HARMONi-2 reported median overall survival of 30.8 months with ivonescimab versus 22.6 months with pembrolizumab in first-line PD-L1-positive NSCLC, while sacituzumab tirumotecan plus pembrolizumab produced a strong interim PFS signal. China-only enrollment, lack of chemoimmunotherapy comparators, immature survival data, and increased toxicity leave global positioning uncertain.